Xtrackers S&P 500 Scored and Screened ETF (SNPE)

Data from OTC Markers

28 shares showing short as of 6/15/26

1 Beneficial Holder of 100 shares as of 12/22/25

DD for those interested

I’ve gotten one response to several inquiries, which steered me to OTC Markets for most reliable data earl

I hope you're doing well man! I'm out of this dumpster fire. I I tried to fool myself I think and maybe This thing goes somewhere, but I had to pull out.

Think Big, "100000 in stock"

https://shop.painkiller.care/products/painkiller%E2%84%A2-actipatch%C2%AE-pallet-1-200-units?pr_prod_strat=e5_desc&pr_rec_id=f01c51e9e&pr_rec_pid=8084178141253&pr_ref_pid=8043131961413&pr_seq=uniform

https://shop.painkiller.care/products/pai

That's hanging around is to see what actually happens in this thing. I don't have the balls to put money in this and nor do I think it's going to do as well as other things can. However, I've been In and out of this dumpster fire for just over 13 years and there's nothing that can convince me this i

I get what you’re saying, yes, MHRA has been consistent for weeks in signaling that NWBO’s silence is self-chosen. But that actually reinforces the point I’m making, not the one you’re making. The fact that MHRA has repeatedly confirmed active review, acknowledged clinical impact, and
redire

Holding all my shares. BULLISH!!!

Holding all my shares. BULLISH!!!

I was supposed to quit for the night with the last post but thought I'd check out Mr. Taylor's LinkedIn and found the following:

https://www.linkedin.com/in/rodolfo-taylor-07b32791/recent-activity/all/

Rodolfo Taylor
Automotive Professional Consultant. Specializi

Even 1-100 split only gets this to $3 and they need $4 to uplist, so not sure how they plan to get there.

Sometimes i wonder how old some people are...........

Online........

Am sure some do have snot running down their nose.......

I try to imagine how boring this job of glued to your desktop or laptop all day.....

One can start playing and co

Because you touch yourself at night

Well, most of have reached the 3.5 year point from our last shot, so we can be confident that the vaccine has cleared. What’s the point of this article?

For a minute there i thought about lucky Gilmore..........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹

LOLOLOLOL!

Buy, buy, buy... Hold, hold, hold... Profit, profit, profit. BULLISH!!!

Nonsense, lol. Craig Marshak holds the Wertheim trademark name and sits on your company's board as a private director of that company, per se, lmao!

500 million more shares added today

Charles Schwab shows $0.10. The chart on E*Trade shows $0.10. I am convinced $0.10 is the true price. I had an order to Sell at $0.10. At this point, I will not sell for less than $0.10. BULLISH!!!

I think GetRch$lwly laid out a reasonable “everything goes perfectly” scenario, but I still think it’s probably too optimistic.

NAMSA absolutely improves the odds of getting the IDE right the first time, but it doesn’t eliminate FDA review timelines or potential questions. They still

🤑SNTX🤑 You All Ready To See A Million + In Your Accounts $🤑$🤑$🤑$🤑$🤑$🤑$🤑Elon Be Liking Mr Leal !

$OSRH what is there not to like 💎 
- $815 million funding for advancing their drug VAXIM while looking for a big pharmaceutical partner during that process.
- $15 million in funding starting in October at $10 a share
- a NDA with a 8 billion in sales company to investiga

$OSRH what is there not to like 💎 
- $815 million funding for advancing their drug VAXIM while looking for a big pharmaceutical partner during that process.
- $15 million in funding starting in October at $10 a share
- a NDA with a 8 billion in sales company to investiga

I know most do not follow charts and think they are useless for low cap bio. They have been right for the last five years. In order for that to change I believe we need to see volume of 10 million shares on big news. Here is the chart.
https://schrts.co/mHVrctPW

• “…recognizing the impact this medicine could potentially have.”
This could be true of every single treatment that is up for approval, as a new treatment not yet available prior to approval,